Engevik AC, Kaji I, Goldenring JR (2020) The physiology of the gastric parietal cell. Physiol Rev 100:573–602. https://doi.org/10.1152/physrev.00016.2019

Article  CAS  PubMed  Google Scholar 

Jo Y, Park E, Ahn SB et al (2015) A proton pump inhibitor’s effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut Liver 9:607–614. https://doi.org/10.5009/gnl14135

Article  CAS  PubMed  Google Scholar 

Gomm W, von Holt K, Thomé F et al (2016) Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 73:410–416. https://doi.org/10.1001/jamaneurol.2015.4791

Article  PubMed  Google Scholar 

Veremme L, Janoly-Dumenil A, Charpiat B (2021) Curbing proton pump inhibitor overprescribing: Multifaceted strategies in an academic hospital. J Clin Pharm Ther 46:1041–1045. https://doi.org/10.1111/jcpt.13395

Article  PubMed  Google Scholar 

Lavan AH, O’Mahony D, O’Mahony D, Gallagher P (2021) Potentially inappropriate medication (PIM) use and severe drug interactions (SDIs) in older adults with cancer. J Geriatr Oncol 12:872–880. https://doi.org/10.1016/j.jgo.2021.02.021

Article  CAS  PubMed  Google Scholar 

Dharmarajan TS (2021) The use and misuse of proton pump inhibitors: an opportunity for deprescribing. J Am Med Dir Assoc 22:15–22. https://doi.org/10.1016/j.jamda.2020.09.046

Article  PubMed  Google Scholar 

Lin D, Eke C, Cai C, Thrift AP, Shukla R (2020) Decreasing overall and inappropriate proton pump inhibitor use: perspective from a large safety-net healthcare system. Clin Gastroenterol Hepatol 18:763–766. https://doi.org/10.1016/j.cgh.2019.12.015

Article  PubMed  Google Scholar 

Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA (2015) Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 10:e0128004. https://doi.org/10.1371/journal.pone.0128004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inghammar M, Svanström H, Voldstedlund M, Melbye M, Hviid A, Mølbak K et al (2021) Proton-pump inhibitor use and the risk of community-associated clostridium difficile infection. Clin Infect Dis 72:e1084–e1089. https://doi.org/10.1093/cid/ciaa1857

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lazarus B, Chen Y, Wilson FP et al (2016) Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176:238–246. https://doi.org/10.1001/jamainternmed.2015.7193

Article  PubMed  PubMed Central  Google Scholar 

Shiraev TP, Bullen A (2018) Proton pump inhibitors and cardiovascular events: A systematic review. Heart Lung Circ 27:443–450. https://doi.org/10.1016/j.hlc.2017.10.020

Article  PubMed  Google Scholar 

Kallam A, Singla A, Silberstein P (2015) Proton pump induced thrombocytopenia: A case report and review of literature. Platelets 26:598–601. https://doi.org/10.3109/09537104.2014.953045

Article  CAS  PubMed  Google Scholar 

Wang Y, Ye Z, Ge L et al (2020) Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. BMJ 368:l6744. https://doi.org/10.1136/bmj.l6744

Article  PubMed  PubMed Central  Google Scholar 

García Rodríguez LA, Lanas A, Soriano-Gabarró M, Vora P, Cea Soriano L (2020) Effect of proton pump inhibitors on risks of upper and lower gastrointestinal bleeding among users of low-dose aspirin: a population-based observational study. J Clin Med 9:928. https://doi.org/10.3390/jcm9040928

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barkun AN, Almadi M, Kuipers EJ et al (2019) Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. Ann Intern Med 171:805–822. https://doi.org/10.7326/M19-1795

Article  PubMed  PubMed Central  Google Scholar 

Ye Z, Reintam Blaser A, Lytvyn L et al (2020) Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ 368. https://doi.org/10.1136/bmj.l6722

Iwakiri R, Tominaga K, Furuta K et al (2013) Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther 38:729–740. https://doi.org/10.1111/apt.12444

Article  CAS  PubMed  Google Scholar 

Takeuchi T, Takahashi Y, Kawaguchi S et al (2018) Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol 33:623–630. https://doi.org/10.1111/jgh.13970

Article  CAS  PubMed  Google Scholar 

Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N (2017) ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 112:988–1013. https://doi.org/10.1038/ajg.2017.154

Article  CAS  PubMed  Google Scholar 

De Biasio JC, Mittel AM, Mueller AL, Ferrante LE, Kim DH, Shaefi S (2020) Frailty in critical care medicine: A review. Anesth Analg 130:1462–1473. https://doi.org/10.1213/ANE.0000000000004665

Article  PubMed  PubMed Central  Google Scholar 

Costarino AT, Dai D, Feng R, Feudtner C, Guevara JP (2015) Gastric acid suppressant prophylaxis in pediatric intensive care: current practice as reflected in a large administrative database. Pediatr Crit Care Med 16:605–612. https://doi.org/10.1097/PCC.0000000000000427

Article  PubMed  Google Scholar 

Zeng X, Yu G, Lu Y, Tan L, Wu X, Shi S et al (2020) PIC, a paediatric-specific intensive care database. Scientific data 7:1–8. https://doi.org/10.1038/s41597-020-0355-4

Article  CAS  Google Scholar 

von Elm Erik, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806–808. https://doi.org/10.1136/bmj.39335.541782.AD

Zhang Z (2017) Propensity score method: a non-parametric technique to reduce model dependence. Ann Transl Med 5:7. https://doi.org/10.21037/atm.2016.08.57

Krag M, Marker S, Perner A et al (2018) Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med 379:2199–2208. https://doi.org/10.1056/NEJMoa1714919

Article  CAS  PubMed  Google Scholar 

Shi L, Zhang D (2020) Proton pump inhibitor use before icu admission is not associated with mortality of critically Ill patients. J Clin Pharmacol 60:860–866. https://doi.org/10.1002/jcph.1585

Article  CAS  PubMed  Google Scholar 

Chen C, Liu H, Duan R, Wang F, Duan L (2021) The efficacy and safety of acid suppressants for gastrointestinal bleeding prophylaxis in cardiac care unit patients. J Gastroenterol Hepatol 36:2131–2140. https://doi.org/10.1111/jgh.15432

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu YH, Cao ZY, Dai YN et al (2022) Association of Proton Pump Inhibitor and Infection and Major Adverse Clinical Events in Patients With ST-Elevation Myocardial Infarction: A Propensity Score Matching Analysis. Front Med 9:882341. https://doi.org/10.3389/fmed.2022.882341

Article  Google Scholar 

Balthazar T, Vandenbriele C, Verbrugge FH et al (2021) Managing patients with short-term mechanical circulatory support: JACC review topic of the week. J Am Coll Cardiol 77:1243–1256. https://doi.org/10.1016/j.jacc.2020.12.054

Article  CAS  PubMed  Google Scholar 

Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D (2010) Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J 74:2187–2192. https://doi.org/10.1253/circj.cj-09-0913

Article  CAS  PubMed  Google Scholar 

Furtado RHM, Giugliano RP, Strunz CMC et al (2016) Drug interaction between clopidogrel and ranitidine or omeprazole in stable coronary artery disease: A double-blind, double dummy. Randomized Study Am J Cardiovasc Drugs 16:275–284. https://doi.org/10.1007/s40256-016-0172-5

Article  CAS  PubMed  Google Scholar 

Goodman SG, Clare R, Pieper KS et al (2012) Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 125:978–986. https://doi.org/10.1161/CIRCULATIONAHA.111.032912

Article  CAS  PubMed  Google Scholar 

Schunack W (1987) What are the differences between the H2-receptor antagonists? Aliment Pharmacol Ther 1:493s–503s. https://doi.org/10.1111/j.1365-2036.1987.tb00658.x

Article  CAS  PubMed  Google Scholar 

Scholtholt J, Bickel M, Herling AW (1988) A review of the animal pharmacology of roxatidine acetate. Drugs 35:30–40. https://doi.org/10.2165/00003495-198800353-00008

Article  CAS  PubMed  Google Scholar 

Zhang J, Cai WK, Zhang Z et al (2018) Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis. Medicine (Baltimore) 97:e0409. https://doi.org/10.1097/MD.0000000000010409

Article  CAS  PubMed  Google Scholar 

Huang YH, Cai WK, Yin SJ et al (2022) Histamine H2 receptor antagonist exposure was related to decreased all-cause mortality in critical ill patients with heart failure: a cohort study. Eur J Prev Cardiol 29:1854–1865. https://doi.org/10.1093/eurjpc/zwac122